Review

mouse melanoma cells b16f1 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC mouse melanoma cells b16f1

<t>B16F1</t> cellular behaviors of A@DFX, AB@DFX and RGD AB@DFX NPs (A) Fluorescence microscopy images of cells treated with various FITC-labeled NPs for 6 h. Scale bars, 10 μm. ( n = 3 independent biological replicates). (B) Cell viability assessment after 24 h of incubation with cells by MTT assay. Data are expressed as means ± SD ( n = 3 independent biological replicates). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (C) Western blot analysis of p -AKT and PD-L1 expression of cells treated with various NPs for 6 h ( n = 3 independent biological replicates).

Mouse Melanoma Cells B16f1, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1196 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+melanoma+cells+b16f1/B16-F1/pmc13049520-40-0-5
Average 97 stars, based on 1196 article reviews

mouse melanoma cells b16f1 - by Bioz Stars, 2026-10

97/100 stars

Images

1) Product Images from "Targeted delivery and controlled release of deferasirox for melanoma therapy"

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

Journal: iScience

doi: 10.1016/j.isci.2026.115303

B16F1 cellular behaviors of A@DFX, AB@DFX and RGD AB@DFX NPs (A) Fluorescence microscopy images of cells treated with various FITC-labeled NPs for 6 h. Scale bars, 10 μm. ( n = 3 independent biological replicates). (B) Cell viability assessment after 24 h of incubation with cells by MTT assay. Data are expressed as means ± SD ( n = 3 independent biological replicates). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (C) Western blot analysis of p -AKT and PD-L1 expression of cells treated with various NPs for 6 h ( n = 3 independent biological replicates).

Figure Legend Snippet: B16F1 cellular behaviors of A@DFX, AB@DFX and RGD AB@DFX NPs (A) Fluorescence microscopy images of cells treated with various FITC-labeled NPs for 6 h. Scale bars, 10 μm. ( n = 3 independent biological replicates). (B) Cell viability assessment after 24 h of incubation with cells by MTT assay. Data are expressed as means ± SD ( n = 3 independent biological replicates). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (C) Western blot analysis of p -AKT and PD-L1 expression of cells treated with various NPs for 6 h ( n = 3 independent biological replicates).

Techniques Used: Fluorescence, Microscopy, Labeling, Incubation, MTT Assay, Western Blot, Expressing

Pharmacokinetics and biodistribution of various NPs in B16F1 tumor-bearing mice (A) Plasma concentration-time curve of DFX of mice intravenously injected with DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs during 24 h. Data are expressed as means ± SD ( n = 3 mice). (B) Ex vivo fluorescence images of tumor and major organs (heart, liver, spleen, lung, and kidney) of mice intravenously injected with DiR-labeled NPs ( RGD AB@DiR NPs, AB@DiR NPs and A@DiR NPs) and DiR; the fluorescence images were collected at 24 h post-injection ( n = 3 mice). (C) Quantitative fluorescence intensity analysis in (B). Data are expressed as means ± SD ( n = 3 mice).

Figure Legend Snippet: Pharmacokinetics and biodistribution of various NPs in B16F1 tumor-bearing mice (A) Plasma concentration-time curve of DFX of mice intravenously injected with DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs during 24 h. Data are expressed as means ± SD ( n = 3 mice). (B) Ex vivo fluorescence images of tumor and major organs (heart, liver, spleen, lung, and kidney) of mice intravenously injected with DiR-labeled NPs ( RGD AB@DiR NPs, AB@DiR NPs and A@DiR NPs) and DiR; the fluorescence images were collected at 24 h post-injection ( n = 3 mice). (C) Quantitative fluorescence intensity analysis in (B). Data are expressed as means ± SD ( n = 3 mice).

Techniques Used: Drug discovery, Clinical Proteomics, Concentration Assay, Injection, Ex Vivo, Fluorescence, Labeling

In vivo therapeutic effect of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) Tumor growth curves during 21 days of treatment with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Data are expressed as means ± SD ( n = 3 mice). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (B) Photographs of tumors at the end of 21 days of various treatments ( n = 3 mice). (C) PD-L1 expression of tumor tissues at the end of 21 days of various treatments ( n = 3 independent biological replicates). (D) H&E staining of tumor tissue sections at the end of 21 days of various treatments. Scale bars, 100 μm.

Figure Legend Snippet: In vivo therapeutic effect of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) Tumor growth curves during 21 days of treatment with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Data are expressed as means ± SD ( n = 3 mice). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (B) Photographs of tumors at the end of 21 days of various treatments ( n = 3 mice). (C) PD-L1 expression of tumor tissues at the end of 21 days of various treatments ( n = 3 independent biological replicates). (D) H&E staining of tumor tissue sections at the end of 21 days of various treatments. Scale bars, 100 μm.

Techniques Used: In Vivo, Expressing, Staining

Biocompatibility of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) H&E staining of major organs (heart, liver, spleen, lung and kidney) at the end of 21 days of treatments with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Scale bars, 100 μm. (B) Blood routine indices of mice at the end of 21 days of various treatments. Data are expressed as means ± SD ( n = 3 mice).

Figure Legend Snippet: Biocompatibility of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) H&E staining of major organs (heart, liver, spleen, lung and kidney) at the end of 21 days of treatments with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Scale bars, 100 μm. (B) Blood routine indices of mice at the end of 21 days of various treatments. Data are expressed as means ± SD ( n = 3 mice).

Techniques Used: Staining

Cell Culture:

Article Title: Contribution of Filopodia to Cell Migration: A Mechanical Link between Protrusion and Contraction.
Article Snippet: .. Mouse melanoma cells B16F1 (ATCC CRL-6323) were cultured in Dulbecco’s modified Eagle’s medium with 10% FBS (Atlanta Biologicals), 2 mM glutamine, 100 μg/mL ampicillin and 100 μg/mL streptomycin at 37◦C in the presence of 5% CO2. ..

Article Title: Contribution of Filopodia to Cell Migration: A Mechanical Link between Protrusion and Contraction
Article Snippet: .. Mouse melanoma cells B16F1 (ATCC CRL-6323) were cultured in Dulbecco's modified Eagle's medium with 10% FBS (Atlanta Biologicals), 2 mM glutamine, 100 μ g/mL ampicillin and 100 μ g/mL streptomycin at 37°C in the presence of 5% CO 2 . .. The full-length human T-plastin sequence was amplified from the a clone containing PLS3 cDNA (ATCC clone 10437180) by polymerase chain reaction with primers containing the restriction sites Eco RI/ Kpn I and cloned into the pEGFP-C1 vector (Clontech, Palo Alto, CA) to produce pEGFP-T-plastin.

Modification:

Mutagenesis:

Article Title: Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents.
Article Snippet: .. The mouse melanoma cells B16F1 and B16F10 (metastatic), the nonsmall cell lung carcinoma cells PC9, and the NSC lung adenocarcinoma with EGFR mutation HCC827, were obtained from the American Type Culture Collection. .. Cells were maintained in DMEM (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Celbio, Milan, Italy) and 2 mM glutamine, 100 units penicillin and 0.1 mg/l streptomycin (Sigma Aldrich, St. Louis, MO, USA).

Image Search Results

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: B16F1 cellular behaviors of A@DFX, AB@DFX and RGD AB@DFX NPs (A) Fluorescence microscopy images of cells treated with various FITC-labeled NPs for 6 h. Scale bars, 10 μm. ( n = 3 independent biological replicates). (B) Cell viability assessment after 24 h of incubation with cells by MTT assay. Data are expressed as means ± SD ( n = 3 independent biological replicates). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (C) Western blot analysis of p -AKT and PD-L1 expression of cells treated with various NPs for 6 h ( n = 3 independent biological replicates).

Article Snippet: Mouse Melanoma Cells (B16F1) , ATCC , CRL-6323.

Techniques: Fluorescence, Microscopy, Labeling, Incubation, MTT Assay, Western Blot, Expressing

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: Pharmacokinetics and biodistribution of various NPs in B16F1 tumor-bearing mice (A) Plasma concentration-time curve of DFX of mice intravenously injected with DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs during 24 h. Data are expressed as means ± SD ( n = 3 mice). (B) Ex vivo fluorescence images of tumor and major organs (heart, liver, spleen, lung, and kidney) of mice intravenously injected with DiR-labeled NPs ( RGD AB@DiR NPs, AB@DiR NPs and A@DiR NPs) and DiR; the fluorescence images were collected at 24 h post-injection ( n = 3 mice). (C) Quantitative fluorescence intensity analysis in (B). Data are expressed as means ± SD ( n = 3 mice).

Article Snippet: Mouse Melanoma Cells (B16F1) , ATCC , CRL-6323.

Techniques: Drug discovery, Clinical Proteomics, Concentration Assay, Injection, Ex Vivo, Fluorescence, Labeling

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: In vivo therapeutic effect of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) Tumor growth curves during 21 days of treatment with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Data are expressed as means ± SD ( n = 3 mice). Statistical analysis: one-way ANOVA followed by Tukey’s post hoc test. ∗ p < 0.05. (B) Photographs of tumors at the end of 21 days of various treatments ( n = 3 mice). (C) PD-L1 expression of tumor tissues at the end of 21 days of various treatments ( n = 3 independent biological replicates). (D) H&E staining of tumor tissue sections at the end of 21 days of various treatments. Scale bars, 100 μm.

Article Snippet: Mouse Melanoma Cells (B16F1) , ATCC , CRL-6323.

Techniques: In Vivo, Expressing, Staining

Journal: iScience

Article Title: Targeted delivery and controlled release of deferasirox for melanoma therapy

doi: 10.1016/j.isci.2026.115303

Figure Lengend Snippet: Biocompatibility of RGD AB@DFX NPs in B16F1 tumor-bearing mice (A) H&E staining of major organs (heart, liver, spleen, lung and kidney) at the end of 21 days of treatments with PBS, A NPs, DFX, A@DFX NPs, AB@DFX NPs and RGD AB@DFX NPs. Scale bars, 100 μm. (B) Blood routine indices of mice at the end of 21 days of various treatments. Data are expressed as means ± SD ( n = 3 mice).

Article Snippet: Mouse Melanoma Cells (B16F1) , ATCC , CRL-6323.

Techniques: Staining

B16F1 cells stably expressing shHrs or control plasmid (shLacZ) were transiently transfected with tdTomato-fTractin and seeded onto PDL-coated glass bottom MatTek Plates 24 hr post-transfection. Live cells were imaged every 30 s for 15 min. Movies were inverted, de-noised, and brightness/contrast was adjusted to facilitate visualization of filopodia.

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: B16F1 cells stably expressing shHrs or control plasmid (shLacZ) were transiently transfected with tdTomato-fTractin and seeded onto PDL-coated glass bottom MatTek Plates 24 hr post-transfection. Live cells were imaged every 30 s for 15 min. Movies were inverted, de-noised, and brightness/contrast was adjusted to facilitate visualization of filopodia.

Article Snippet: B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS.

Techniques:

B16F1 cells stably expressing shEng or control plasmid (shScr) were transiently transfected with tdTomato-fTractin and seeded onto PDL-coated glass bottom MatTek plates 24 hr post-transfection. Live cells were imaged every 30 s for 15 min. Movies were inverted and brightness/contrast was adjusted to facilitate visualization of filopodia.

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: B16F1 cells stably expressing shEng or control plasmid (shScr) were transiently transfected with tdTomato-fTractin and seeded onto PDL-coated glass bottom MatTek plates 24 hr post-transfection. Live cells were imaged every 30 s for 15 min. Movies were inverted and brightness/contrast was adjusted to facilitate visualization of filopodia.

Article Snippet: B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS.

Techniques:

$( A ) Western blot of Hrs-KD in B16F1 cells. ( B ) Western blot of Rab27a-KD in B16F1 cells. ( C ) Nanoparticle tracking analysis representative traces showing particle size distributions that correspond to the data for control SEVs and LEVs in . ( D ) Western blot of gradient fractions for SEVs prepared by the cushion density gradient (DG) method. TCL, total cell lysate. LEVs also run on gel. ( E ) TEM of negatively stained LEVs and SEVs prepared by the cushion-DG method. Scale bar = 200 nm in each image. Figure 2—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 2—figure supplement 1—source data 2. Original files for western blot analysis displayed in . Figure 2—figure supplement 1—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 2—figure supplement 1—source data 4. Original files for western blot analysis displayed in . Figure 2—figure supplement 1—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 2—figure supplement 1—source data 6. Original files for western blot analysis displayed in .$

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Western blot of Hrs-KD in B16F1 cells. ( B ) Western blot of Rab27a-KD in B16F1 cells. ( C ) Nanoparticle tracking analysis representative traces showing particle size distributions that correspond to the data for control SEVs and LEVs in . ( D ) Western blot of gradient fractions for SEVs prepared by the cushion density gradient (DG) method. TCL, total cell lysate. LEVs also run on gel. ( E ) TEM of negatively stained LEVs and SEVs prepared by the cushion-DG method. Scale bar = 200 nm in each image. Figure 2—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 2—figure supplement 1—source data 2. Original files for western blot analysis displayed in . Figure 2—figure supplement 1—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 2—figure supplement 1—source data 4. Original files for western blot analysis displayed in . Figure 2—figure supplement 1—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 2—figure supplement 1—source data 6. Original files for western blot analysis displayed in .

Article Snippet: B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS.

Techniques: Western Blot, Control, Staining

( A ) EVs secreted from equal numbers of control (shLacZ), Rab27a-KD, and Hrs-KD B16F1 cells over 48 hr were quantified using NanoSight particle tracking analysis (N=3 biological replicates). ( B ) Representative images of control (shLacZ), Hrs-KD, and Rab27a-KD B16F1 cells stained with rhodamine-phalloidin. Arrowheads show examples of filopodia. Images have been edited with brightness and contrast for ease of visibility. ( C ) Quantification of filopodia from images as in B (≥27 total cells per condition from three biological replicates). Filopodia number per 500 mm 2 cell area. ( D ) Representative images of filopodia in B16F1 control (shLacZ) and exosome-depleted (shHrs) cells treated for 18 hr with LEVs or SEVs isolated from control cells. Arrowheads show examples of filopodia. Images have been edited with brightness and contrast for ease of visibility. ( E ) Quantification of filopodia from images as in D (≥20 total cells per condition from three biological replicates). ( F ) Filopodia number in B16F1 shScr cells treated with indicated numbers of purified LEVs or SEVs, for 18 hr (≥25 total cells per condition from three biological replicates). ( G ) Control (shLacZ) and exosome-depleted (shHrs) B16F1 cells were transiently transfected with tdTomato-F-tractin to visualize filopodia formation. Live images were taken every 30 s for 15 min and newly formed filopodia were counted at each time point. Only filopodia that form and fully retract during the duration of the video were quantified. (≥20 total cells per type per biological replicate, from three biological replicates). ( H ) Lifetime of newly formed filopodia from G. Lifetime is defined as the time from first formation of the filopodia to full retraction. Bars represent mean and error bars are SEM. Scale bars in wide field and zoom insets = 10 mm. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) EVs secreted from equal numbers of control (shLacZ), Rab27a-KD, and Hrs-KD B16F1 cells over 48 hr were quantified using NanoSight particle tracking analysis (N=3 biological replicates). ( B ) Representative images of control (shLacZ), Hrs-KD, and Rab27a-KD B16F1 cells stained with rhodamine-phalloidin. Arrowheads show examples of filopodia. Images have been edited with brightness and contrast for ease of visibility. ( C ) Quantification of filopodia from images as in B (≥27 total cells per condition from three biological replicates). Filopodia number per 500 mm 2 cell area. ( D ) Representative images of filopodia in B16F1 control (shLacZ) and exosome-depleted (shHrs) cells treated for 18 hr with LEVs or SEVs isolated from control cells. Arrowheads show examples of filopodia. Images have been edited with brightness and contrast for ease of visibility. ( E ) Quantification of filopodia from images as in D (≥20 total cells per condition from three biological replicates). ( F ) Filopodia number in B16F1 shScr cells treated with indicated numbers of purified LEVs or SEVs, for 18 hr (≥25 total cells per condition from three biological replicates). ( G ) Control (shLacZ) and exosome-depleted (shHrs) B16F1 cells were transiently transfected with tdTomato-F-tractin to visualize filopodia formation. Live images were taken every 30 s for 15 min and newly formed filopodia were counted at each time point. Only filopodia that form and fully retract during the duration of the video were quantified. (≥20 total cells per type per biological replicate, from three biological replicates). ( H ) Lifetime of newly formed filopodia from G. Lifetime is defined as the time from first formation of the filopodia to full retraction. Bars represent mean and error bars are SEM. Scale bars in wide field and zoom insets = 10 mm. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001.

Article Snippet: B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS.

Techniques: Control, Staining, Isolation, Purification, Transfection

( A ) Purified LEVs and SEVs were run on a colloidal blue-stained gel. Four arrows denote SEV bands that were cut and submitted for proteomics, along with notable proteins identified (see for the full proteomics results). ( B ) B16F1 total cell lysate (TCL), LEVs, and density gradient purified SEVs were run on an SDS-PAGE gel and probed by western blot for endoglin, and EV positive (HSP70, TSG101, flotillin-1, and CD63) and negative (GM130) markers. ( C ) Total cell lysate (TCL) and small EVs (SEVs) from endoglin-KD (shEng) and control (shScr) B16F1 cells were run on an SDS-PAGE gel and probed by western blot for endoglin, EV marker TSG101, and EV-negative marker GM130. ( D ) Representative images from control (shScr) or endoglin-KD (shEng) B16F1 cell lines incubated for 18 hr with no EVs (left panels), or with SEVs purified from control (+shScr SEVs) or shEng cell lines (+shEng SEVs) (right panels). Arrowheads indicate example filopodia. Scale bar = 10 mm. ( E ) Quantification of filopodia in control (shScr) and endoglin knockdown (shEng) cells treated with the indicated number of LEVs or SEVs for 18 hr (≥20 cells per condition per biological replicate, from three biological replicates). ( F ) Filopodia number in B16F1 control (shLacZ) or exosome-depleted (shHrs) cells treated with indicated numbers of LEVs, control (shScr) SEVs, or endoglin-KD (shEng1) SEVs for 18 hr. ≥20 cells per condition per biological replicate, from three biological replicates. Representative images for this experiment are shown in . ( G, H ) B16F1 cells were transfected with tdTomato-F-Tractin and imaged live every 30 s for 15 min. Only filopodia that form and fully retract during the duration of each video were quantified. ( G ) De novo filopodia formation. ( H ) Filopodia lifetime, defined as the time from initial filopodia formation to full retraction. Bars represent mean and error bars are SEM. (³25 total cells per type per biological replicate, from three biological replicates) ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—source data 1. PDF file containing original blot for , indicating the relevant bands. Figure 4—source data 2. Original file for Coomassie blue gel displayed in . Figure 4—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 4. Original files for western blot analysis displayed in . Figure 4—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 6. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Purified LEVs and SEVs were run on a colloidal blue-stained gel. Four arrows denote SEV bands that were cut and submitted for proteomics, along with notable proteins identified (see for the full proteomics results). ( B ) B16F1 total cell lysate (TCL), LEVs, and density gradient purified SEVs were run on an SDS-PAGE gel and probed by western blot for endoglin, and EV positive (HSP70, TSG101, flotillin-1, and CD63) and negative (GM130) markers. ( C ) Total cell lysate (TCL) and small EVs (SEVs) from endoglin-KD (shEng) and control (shScr) B16F1 cells were run on an SDS-PAGE gel and probed by western blot for endoglin, EV marker TSG101, and EV-negative marker GM130. ( D ) Representative images from control (shScr) or endoglin-KD (shEng) B16F1 cell lines incubated for 18 hr with no EVs (left panels), or with SEVs purified from control (+shScr SEVs) or shEng cell lines (+shEng SEVs) (right panels). Arrowheads indicate example filopodia. Scale bar = 10 mm. ( E ) Quantification of filopodia in control (shScr) and endoglin knockdown (shEng) cells treated with the indicated number of LEVs or SEVs for 18 hr (≥20 cells per condition per biological replicate, from three biological replicates). ( F ) Filopodia number in B16F1 control (shLacZ) or exosome-depleted (shHrs) cells treated with indicated numbers of LEVs, control (shScr) SEVs, or endoglin-KD (shEng1) SEVs for 18 hr. ≥20 cells per condition per biological replicate, from three biological replicates. Representative images for this experiment are shown in . ( G, H ) B16F1 cells were transfected with tdTomato-F-Tractin and imaged live every 30 s for 15 min. Only filopodia that form and fully retract during the duration of each video were quantified. ( G ) De novo filopodia formation. ( H ) Filopodia lifetime, defined as the time from initial filopodia formation to full retraction. Bars represent mean and error bars are SEM. (³25 total cells per type per biological replicate, from three biological replicates) ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—source data 1. PDF file containing original blot for , indicating the relevant bands. Figure 4—source data 2. Original file for Coomassie blue gel displayed in . Figure 4—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 4. Original files for western blot analysis displayed in . Figure 4—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—source data 6. Original files for western blot analysis displayed in .

Article Snippet: B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS.

Techniques: Purification, Staining, SDS Page, Western Blot, Control, Marker, Incubation, Knockdown, Transfection

( A ) Nanoparticle tracking analysis traces for B16F1 control (shScr) and endoglin-KD (shEng) SEVs. ( B ) SEV secretion rates from B16F1 shEng stable lines. N=5 biological replicates. ( C ) Representative western blot of Endoglin-KD in transient siRNA-transfected B16F1 cells. ( D ) Filopodia numbers in siRNA-transfected B16F1 cells (≥23 cells per condition per biological replicate, from three biological replicates). ( E ) Images from control and shHrs cells incubated with purified EV, corresponding to graph in . Scale bar in wide field and zoom insets = 10 mm. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—figure supplement 1—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Nanoparticle tracking analysis traces for B16F1 control (shScr) and endoglin-KD (shEng) SEVs. ( B ) SEV secretion rates from B16F1 shEng stable lines. N=5 biological replicates. ( C ) Representative western blot of Endoglin-KD in transient siRNA-transfected B16F1 cells. ( D ) Filopodia numbers in siRNA-transfected B16F1 cells (≥23 cells per condition per biological replicate, from three biological replicates). ( E ) Images from control and shHrs cells incubated with purified EV, corresponding to graph in . Scale bar in wide field and zoom insets = 10 mm. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 4—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 4—figure supplement 1—source data 2. Original files for western blot analysis displayed in .

Article Snippet: B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS.

Techniques: Control, Western Blot, Transfection, Incubation, Purification

( A ) Western blot showing b1-integrin, TGFb1, ALK1 levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. ( B ) Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9.≥20 cells per condition per biological replicate, from three biological replicates. ( C ) Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFb1.≥20 cells per condition per biological replicate, from three biological replicates. ( D ) Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). ≥20 cells per condition per biological replicate, from three biological replicates. ( E ) Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. ≥20 cells per condition per biological replicate, from biological replicates. Figure 6—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—figure supplement 1—source data 2. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Western blot showing b1-integrin, TGFb1, ALK1 levels in control (shScr) and endoglin-KD (shEng) B16F1 SEVs. ( B ) Filopodia density analysis of B16F1 shScr and shEng cells treated with BMP-9.≥20 cells per condition per biological replicate, from three biological replicates. ( C ) Filopodia density analysis of B16F1 shScr and shEng cells treated with TGFb1.≥20 cells per condition per biological replicate, from three biological replicates. ( D ) Filopodia density analysis of B16F1 shScr and shEng cells plated on 20 µg/ml fibronectin (FN) or 100 µg/mL poly-D-lysine (PDL). ≥20 cells per condition per biological replicate, from three biological replicates. ( E ) Filopodia density analysis of B16F1 shScr and shEng cells plated on PDL or 2 µg/mL rhTHSD7A for the indicated time points, then fixed and stained for filopodia. ≥20 cells per condition per biological replicate, from biological replicates. Figure 6—figure supplement 1—source data 1. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—figure supplement 1—source data 2. Original files for western blot analysis displayed in .

Article Snippet: B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS.

Techniques: Western Blot, Control, Staining

( A ) Native gel Western blot of B16F1 SEVs. ( B ) Standard western blot of HT1080 SEVs. ( C ) Western blot of cortical neuron total cell lysate (TCL) and SEVs. ( D ) Representative images and quantitation of filopodia number in control (lipofectamine) and THSD7A-mScarlet-transfected HT1080 cells. Arrowheads indicate THSD7A at the ends of filopodia (white arrowheads) or in extracellular deposits (red arrowheads). Scale bars in wide field and zoom insets = 10 mm. ( E ) (Left) Western blot of control shRNA (NTC) and shTHSD7A (C-04, C05, C-06) - expressing HT1080 cell lines. Vinculin is used as a loading control and numbers below the blot indicate normalized THSD7A levels. (Right) Filopodia counts in control and shTHSD7A HT1080 cells. ≥20 cells per condition per biological replicate, from three biological replicates. ( F ) THSD7A coated coverslips rescue filopodia defect in shEng B16F1 and HT1080 cells.≥20 cells per condition per biological replicate, from three biological replicates. ( G, H ) Cortical neurons were transfected with a FLAG-THSD7A expression vector or vector control, fixed, and stained with an antibody against THSD7A, and imaged by confocal microscopy. ( G ) Representative images. Arrows indicate THSD7A localization to the tips of filopodia. Scale bar = 5 mm. ( H ) Quantification of filopodia in neurons expressing FLAG-THSD7A or control vector. n=42 neurons from three separate experiments (biological replicates). ( I ) Rescue of filopodia numbers in shHrs neurons plated on dishes coated with various concentrations of recombinant human THSD7A, as indicated. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 6—source data 1. PDF file containing the original western blots and Ponceau stain from , indicating the relevant bands. Figure 6—source data 2. Original files for western blot and Ponceau analysis displayed in . Figure 6—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—source data 4. Original files for western blot analysis displayed in . Figure 6—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—source data 6. Original files for western blot analysis displayed in . Figure 6—source data 7. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—source data 8. Original files for western blot analysis displayed in .

Journal: eLife

Article Title: Secreted exosomes induce filopodia formation

doi: 10.7554/eLife.101673

Figure Lengend Snippet: ( A ) Native gel Western blot of B16F1 SEVs. ( B ) Standard western blot of HT1080 SEVs. ( C ) Western blot of cortical neuron total cell lysate (TCL) and SEVs. ( D ) Representative images and quantitation of filopodia number in control (lipofectamine) and THSD7A-mScarlet-transfected HT1080 cells. Arrowheads indicate THSD7A at the ends of filopodia (white arrowheads) or in extracellular deposits (red arrowheads). Scale bars in wide field and zoom insets = 10 mm. ( E ) (Left) Western blot of control shRNA (NTC) and shTHSD7A (C-04, C05, C-06) - expressing HT1080 cell lines. Vinculin is used as a loading control and numbers below the blot indicate normalized THSD7A levels. (Right) Filopodia counts in control and shTHSD7A HT1080 cells. ≥20 cells per condition per biological replicate, from three biological replicates. ( F ) THSD7A coated coverslips rescue filopodia defect in shEng B16F1 and HT1080 cells.≥20 cells per condition per biological replicate, from three biological replicates. ( G, H ) Cortical neurons were transfected with a FLAG-THSD7A expression vector or vector control, fixed, and stained with an antibody against THSD7A, and imaged by confocal microscopy. ( G ) Representative images. Arrows indicate THSD7A localization to the tips of filopodia. Scale bar = 5 mm. ( H ) Quantification of filopodia in neurons expressing FLAG-THSD7A or control vector. n=42 neurons from three separate experiments (biological replicates). ( I ) Rescue of filopodia numbers in shHrs neurons plated on dishes coated with various concentrations of recombinant human THSD7A, as indicated. Error bars, SEM. ns, not significant; * p<0.05; ** p<0.01; *** p<0.001. Figure 6—source data 1. PDF file containing the original western blots and Ponceau stain from , indicating the relevant bands. Figure 6—source data 2. Original files for western blot and Ponceau analysis displayed in . Figure 6—source data 3. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—source data 4. Original files for western blot analysis displayed in . Figure 6—source data 5. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—source data 6. Original files for western blot analysis displayed in . Figure 6—source data 7. PDF file containing the original western blots from , indicating the relevant bands. Figure 6—source data 8. Original files for western blot analysis displayed in .

Article Snippet: B16F1 mouse melanoma cells (ATCC CRL-6323) were maintained in DMEM supplemented with 10% FBS.

Techniques: Western Blot, Quantitation Assay, Control, Transfection, shRNA, Expressing, Plasmid Preparation, Staining, Confocal Microscopy, Recombinant

Inflammatory profiles of AT-3 mammary tumors and B16F1 melanoma. AT-3 and B16F1 tumors were grown in C57BL/6 mice for 21 days and 14 days, respectively. (A) Comparative heatmap showing cytokines and chemokines expressed in AT-3 and B16F1 tumors using Proteome Profiler array ( n = 4 tumors, p < 0.05). (B) Representative images and quantification of CD45 staining in AT-3 and B16F1 tumors. n = 8 AT-3 and 6 B16F1 tumors, each dot represents the mean value calculated from 5 random images taken with a 10x objective per tumor. (C) Comparison of granzyme B levels in AT-3 and B16F1 tumor extracts. ( n = 32 AT-3 and 25 B16F1 tumors). (D) Scatter plot of Spearman’s rank correlation between tumor weight and granzyme B in AT-3 ( n = 32) and B16F1 tumors ( n = 25). (E) Comparison of PD-L1 levels in AT-3 ( n = 19) and B16F1 tumors ( n = 14)

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

doi: 10.1186/s13046-024-03001-2

Figure Lengend Snippet: Inflammatory profiles of AT-3 mammary tumors and B16F1 melanoma. AT-3 and B16F1 tumors were grown in C57BL/6 mice for 21 days and 14 days, respectively. (A) Comparative heatmap showing cytokines and chemokines expressed in AT-3 and B16F1 tumors using Proteome Profiler array ( n = 4 tumors, p < 0.05). (B) Representative images and quantification of CD45 staining in AT-3 and B16F1 tumors. n = 8 AT-3 and 6 B16F1 tumors, each dot represents the mean value calculated from 5 random images taken with a 10x objective per tumor. (C) Comparison of granzyme B levels in AT-3 and B16F1 tumor extracts. ( n = 32 AT-3 and 25 B16F1 tumors). (D) Scatter plot of Spearman’s rank correlation between tumor weight and granzyme B in AT-3 ( n = 32) and B16F1 tumors ( n = 25). (E) Comparison of PD-L1 levels in AT-3 ( n = 19) and B16F1 tumors ( n = 14)

Article Snippet: The mouse B16F1 melanoma cell line characterized by a low metastatic potential [ ], was purchased from ATCC.

Techniques: Staining, Comparison

Angiogenic profiles of AT-3 mammary tumors and B16F1 melanoma. (A) Comparative heatmap of angiogenic factors expressed in AT-3 and B16F1 tumor extracts using Proteome Profiler array ( n = 4 tumors, p < 0.05). (B) Representative images of collagen IV staining in AT-3 and B16F1 tumors. (C) Quantification of blood vessels identified by collagen IV staining in AT-3 and B16F1 tumors. n = 8 AT-3 and 6 B16F1 tumors, each dot represents the mean value calculated from 5 random images taken with a 10x objective per tumor. (D) Quantification of mean vessel perimeter in AT-3 and B16F1 tumors. n = 8 AT-3 and 6 B16F1 tumors; each dot represents the mean value calculated from 10 random images taken with a 10x objective per tumor. (E) Tumor vascular perfusion as assessed by measurement of intratumor FITC-dextran content of B16F1 and AT-3 tumors explanted 5 min after intravenous injection of FITC-dextran, 150 kDa. ( n = 27 AT-3 and 20 B16F1 tumors). (F) H&E staining of both tumor types showing tumor bleeding only in B16F1 tumors. Arrows indicate intratumor hemorrhage. Comparison of intratumor hemoglobin content between AT-3 ( n = 32) and B16F1 tumors ( n = 25). ns, non-significant

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

doi: 10.1186/s13046-024-03001-2

Figure Lengend Snippet: Angiogenic profiles of AT-3 mammary tumors and B16F1 melanoma. (A) Comparative heatmap of angiogenic factors expressed in AT-3 and B16F1 tumor extracts using Proteome Profiler array ( n = 4 tumors, p < 0.05). (B) Representative images of collagen IV staining in AT-3 and B16F1 tumors. (C) Quantification of blood vessels identified by collagen IV staining in AT-3 and B16F1 tumors. n = 8 AT-3 and 6 B16F1 tumors, each dot represents the mean value calculated from 5 random images taken with a 10x objective per tumor. (D) Quantification of mean vessel perimeter in AT-3 and B16F1 tumors. n = 8 AT-3 and 6 B16F1 tumors; each dot represents the mean value calculated from 10 random images taken with a 10x objective per tumor. (E) Tumor vascular perfusion as assessed by measurement of intratumor FITC-dextran content of B16F1 and AT-3 tumors explanted 5 min after intravenous injection of FITC-dextran, 150 kDa. ( n = 27 AT-3 and 20 B16F1 tumors). (F) H&E staining of both tumor types showing tumor bleeding only in B16F1 tumors. Arrows indicate intratumor hemorrhage. Comparison of intratumor hemoglobin content between AT-3 ( n = 32) and B16F1 tumors ( n = 25). ns, non-significant

Article Snippet: The mouse B16F1 melanoma cell line characterized by a low metastatic potential [ ], was purchased from ATCC.

Techniques: Staining, Injection, Comparison

Continuous presence of intravascular and firmly adherent platelets in AT-3 mammary tumors and B16F1 melanoma. AT-3 or B16F1 cells were injected subcutaneously in the dorsal skin and allowed to grow for 5 to 7 days before surgical implantation of a dorsal skinfold chamber. Representative intravital images of the microcirculation of B16F1 and AT-3 tumors in mice injected with FITC-dextran and fluorescent antibodies to GPIX, fibrin, Gr-1, or PECAM-1, as indicated. White arrow indicates individual platelets adhering firmly to tumor vessels. The asterisk indicates a platelet-fibrin deposit. The white arrowhead shows a platelet-neutrophil complex adhering to tumor vessels. Bar = 10μm

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

doi: 10.1186/s13046-024-03001-2

Figure Lengend Snippet: Continuous presence of intravascular and firmly adherent platelets in AT-3 mammary tumors and B16F1 melanoma. AT-3 or B16F1 cells were injected subcutaneously in the dorsal skin and allowed to grow for 5 to 7 days before surgical implantation of a dorsal skinfold chamber. Representative intravital images of the microcirculation of B16F1 and AT-3 tumors in mice injected with FITC-dextran and fluorescent antibodies to GPIX, fibrin, Gr-1, or PECAM-1, as indicated. White arrow indicates individual platelets adhering firmly to tumor vessels. The asterisk indicates a platelet-fibrin deposit. The white arrowhead shows a platelet-neutrophil complex adhering to tumor vessels. Bar = 10μm

Article Snippet: The mouse B16F1 melanoma cell line characterized by a low metastatic potential [ ], was purchased from ATCC.

Techniques: Injection

Impact of chronic severe thrombocytopenia on proliferation and apoptosis in B16F1 and AT-3 tumors. (A) Schematic representation of severe chronic thrombocytopenia induction. Starting from the day of B16F1 and AT-3 tumor cell implantation, c-mpl-deficient mice were injected every 5 days with a platelet-depleting polyclonal antibody at low dose (0.5 µg/g mouse). Littermate control mice were injected with a non-immune IgG. (B) Wet weight of B16F1 tumors (platelet 100%, n = 27; <10%, n = 24) and AT-3 tumors (platelet 100%, n = 28; <10%, n = 32). (C) Quantification of KI67-positive cells in B16F1 tumors and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia. n = 7 (100%) and 9 (< 10%) different B16F1 tumors; and n = 7 (100%) and 8 (< 10%) different AT-3 tumors. (D) Quantification of TUNEL-positive cells in B16F1 tumors and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia mice. n = 7 (100%) and 9 (< 10%) different B16F1 tumors; and n = 5 (100%) and 7 (< 10%) different AT-3 tumors. ns: non-significant

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

doi: 10.1186/s13046-024-03001-2

Figure Lengend Snippet: Impact of chronic severe thrombocytopenia on proliferation and apoptosis in B16F1 and AT-3 tumors. (A) Schematic representation of severe chronic thrombocytopenia induction. Starting from the day of B16F1 and AT-3 tumor cell implantation, c-mpl-deficient mice were injected every 5 days with a platelet-depleting polyclonal antibody at low dose (0.5 µg/g mouse). Littermate control mice were injected with a non-immune IgG. (B) Wet weight of B16F1 tumors (platelet 100%, n = 27; <10%, n = 24) and AT-3 tumors (platelet 100%, n = 28; <10%, n = 32). (C) Quantification of KI67-positive cells in B16F1 tumors and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia. n = 7 (100%) and 9 (< 10%) different B16F1 tumors; and n = 7 (100%) and 8 (< 10%) different AT-3 tumors. (D) Quantification of TUNEL-positive cells in B16F1 tumors and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia mice. n = 7 (100%) and 9 (< 10%) different B16F1 tumors; and n = 5 (100%) and 7 (< 10%) different AT-3 tumors. ns: non-significant

Article Snippet: The mouse B16F1 melanoma cell line characterized by a low metastatic potential [ ], was purchased from ATCC.

Techniques: Injection, Control, TUNEL Assay

Impact of thrombocytopenia on vascular permeability and endothelial integrity in B16F1 and AT-3 tumors. A. Representative images of the macroscopic aspects of B16F1 and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia, with or without intravenous injection of FITC-dextran, 2000 kDa prior to sacrifice. AT-3 tumors in control mice are highlighted by white arrows. B-C. Representative images and corresponding endothelial integrity scores of PECAM-1 ( B ) and VE-cadherin ( C ) staining for evaluation of endothelial integrity in AT-3 and B16F1 tumors from control mice and mice with chronic severe thrombocytopenia. Maximal intensity projections of optical sections are shown. D. Comparison of soluble PECAM-1 levels in plasma from control mice and mice with chronic severe thrombocytopenia with AT-3 (platelet 100%, n = 8; <10%, n = 5) or B16F1 (platelet 100%, n = 21; <10%, n = 12) tumors. ns: non-significant

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

doi: 10.1186/s13046-024-03001-2

Figure Lengend Snippet: Impact of thrombocytopenia on vascular permeability and endothelial integrity in B16F1 and AT-3 tumors. A. Representative images of the macroscopic aspects of B16F1 and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia, with or without intravenous injection of FITC-dextran, 2000 kDa prior to sacrifice. AT-3 tumors in control mice are highlighted by white arrows. B-C. Representative images and corresponding endothelial integrity scores of PECAM-1 ( B ) and VE-cadherin ( C ) staining for evaluation of endothelial integrity in AT-3 and B16F1 tumors from control mice and mice with chronic severe thrombocytopenia. Maximal intensity projections of optical sections are shown. D. Comparison of soluble PECAM-1 levels in plasma from control mice and mice with chronic severe thrombocytopenia with AT-3 (platelet 100%, n = 8; <10%, n = 5) or B16F1 (platelet 100%, n = 21; <10%, n = 12) tumors. ns: non-significant

Article Snippet: The mouse B16F1 melanoma cell line characterized by a low metastatic potential [ ], was purchased from ATCC.

Techniques: Permeability, Control, Injection, Staining, Comparison, Clinical Proteomics

Impact of chronic severe thrombocytopenia on the inflammatory and immune profiles of B16F1 and AT-3 tumors. A-B. Comparative heatmap of tumor cytokines and angiogenic factors expressed in ( A ) B16F1 and ( B ) AT-3 tumor extracts from control mice and mice with chronic severe thrombocytopenia mice using Proteome Profiler arrays ( n = 4 tumors per group, p < 0.05). C. Comparison of myeloperoxidase (MPO) levels used as a marker of neutrophil infiltration in B16F1 and AT-3 tumor extracts from control mice and mice with chronic severe thrombocytopenia. n = 25 (100%) and 22 (< 10%) B16F1 tumors; n = 24 (100%) and 29 (< 10%) AT-3 tumors. D. Quantification of CD45-positive cells in B16F1 and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia. n = 9 (100%) and 10 (< 10%) different B16F1 tumors; and n = 9 (100%) and 8 (< 10%) different AT-3 tumors. E. Comparison of cytotoxic cell infiltration among control mice and mice with chronic severe thrombocytopenia in B16F1 and AT-3 tumors by measurement of their granzyme B content. n = 25 (100%) and 22 (< 10%) different B16F1 tumors; and n = 20 (100%) and 30 (< 10%) different AT-3 tumors. ns: non-significant

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

doi: 10.1186/s13046-024-03001-2

Figure Lengend Snippet: Impact of chronic severe thrombocytopenia on the inflammatory and immune profiles of B16F1 and AT-3 tumors. A-B. Comparative heatmap of tumor cytokines and angiogenic factors expressed in ( A ) B16F1 and ( B ) AT-3 tumor extracts from control mice and mice with chronic severe thrombocytopenia mice using Proteome Profiler arrays ( n = 4 tumors per group, p < 0.05). C. Comparison of myeloperoxidase (MPO) levels used as a marker of neutrophil infiltration in B16F1 and AT-3 tumor extracts from control mice and mice with chronic severe thrombocytopenia. n = 25 (100%) and 22 (< 10%) B16F1 tumors; n = 24 (100%) and 29 (< 10%) AT-3 tumors. D. Quantification of CD45-positive cells in B16F1 and AT-3 tumors from control mice and mice with chronic severe thrombocytopenia. n = 9 (100%) and 10 (< 10%) different B16F1 tumors; and n = 9 (100%) and 8 (< 10%) different AT-3 tumors. E. Comparison of cytotoxic cell infiltration among control mice and mice with chronic severe thrombocytopenia in B16F1 and AT-3 tumors by measurement of their granzyme B content. n = 25 (100%) and 22 (< 10%) different B16F1 tumors; and n = 20 (100%) and 30 (< 10%) different AT-3 tumors. ns: non-significant

Article Snippet: The mouse B16F1 melanoma cell line characterized by a low metastatic potential [ ], was purchased from ATCC.

Techniques: Control, Comparison, Marker

Review

mouse melanoma cells b16f1 (ATCC)

Structured Review

Images

1) Product Images from "Targeted delivery and controlled release of deferasirox for melanoma therapy"

Related Articles

Cell Culture:

Modification:

Mutagenesis:

Similar Products

Image Search Results